Medinet, University of Tokyo Hospital Jointly Undertake Animal Experiments for Immune Cell Therapy.Tokyo, Japan, Dec 19, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Medinet announced on December 19 that it has launched basic research into immune cell therapy in collaboration with the University of Tokyo “Todai” redirects here. For the restaurant called Todai, see Todai (restaurant). The University of Tokyo (東京大学 Hospital. Specifically, the two partners have begun animal experiments to assess the efficacy of activated autolymphocyte therapy autolymphocyte therapy Experimental oncology A form of immunotherapy for treating metastatic renal carcinoma, in which a Pt's WBCs are removed, stimulated by monoclonal antibodies, which causes the WBCs to produce and secrete cytokines; the cytokine supernatant is and dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. therapy in the treatment of various cancers. Upon acquiring sufficient results, the two partners will proceed with research with a view to using them in clinical applications. Once a new immune cell therapy is established, it will be applied to patients by the University of Tokyo Hospital as well as by other hospitals. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion